Pregabalin on Hdac2 and Inpp5f levels in rats with CCI-induced neuropathic pain

Hdac2/Inpp5f on the therapeutic effect of pregabalin on neuropathic pain in chronic constriction injury (CCI) rats was investigated. A total of 90 healthy SD rats were selected and divided into the treatment group, the model control group and the normal control group with 30 rats in each group. Rats in the treatment and model control groups were used to construct CCI model. The control group was treated with sham surgery. The model control group was not treated after surgery. The treatment group was treated with pregabalin on the 8th day after operation. Behavioral experiments were performed to measure mechanical withdrawal threshold (MWT) and thermal withdrawal latency (TWL). The expression of inflammatory cytokines TNFα and IL-1β was detected by ELISA kit and expression of Hdac2 and Inpp5f mRNA was detected by RT-qPCR. Before treatment, compared with the normal control group, MWT and TWL values of the treatment and model control groups were significantly decreased (P<0.05). At different time-points after treatment, MWT and TWL were higher in the treatment group than in the model control group and were lower than in the normal control group. At 21 days after operation, the levels of TNFα and IL-1β in the model control and treatment groups were higher than those in the normal control group (P<0.05). The expression level of Hdac2 was higher in the treatment group than in the normal control group (P<0.05). The expression level of Inpp5f mRNA in the treatment and normal control groups was significantly higher than that in the model control group (P<0.05), but the expression level of Inpp5f mRNA in the treatment group was lower than that in the normal control group (P<0.05). Therefore, pregabalin can effectively relieve neuropathic pain in CCI rats, and its efficacy is related to Hdac2 and Inpp5f. Our study provides reference for clinical treatment of neuropathic pain induced by CCI.